TY  - ADVS
AU  - Cragg,Mark
TI  - Monoclonal antibodies in haemato-oncology
T2  - Monoclonal antibodies as therapeutic agents : fundamentals, therapeutic applications and latest advances,
PY  - 2020///
CY  - London
PB  - Henry Stewart Talks
KW  - Antineoplastic agents
KW  - Lymphoma
KW  - Chemotherapy
KW  - Monoclonal antibodies
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Antineoplastic Agents, Immunological
KW  - B-Lymphocytes
KW  - Immunity, Cellular
KW  - drug therapy
KW  - Macrophages
KW  - obinutuzumab
KW  - Receptors, IgG
KW  - drug effects
KW  - metabolism
KW  - Rituximab
KW  - phamacology
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: Introduction to the development and clinical use of monoclonal antibodies (mAb) in haemato-oncology -- Currently approved mAb for treating cancer -- Direct targeting antibodies -- Rituximab -- Fc gamma receptors (FcgR) as key mediators of cellular immunity -- Macrophages as key effector cells -- B cell deletion as a paradigm for mAb effects -- Type I versus Type II antibodies -- Obinutuzumab -- Immunomodulatory mAb -- Combinations between direct targeting and immunomodulatory mAb; Access restricted to subscribers
UR  - https://hstalks.com/bs/4266/
UR  - https://hstalks.com/bs/p/30/
ER  -